-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VH7cyLtVTHC/q2ZZkUiPmFSAeLsdtmvqdSalBt3yfyxixR2OKH2DD4UHnyyQgMzs A3sWAPTURuZIEADAlnQtOg== 0001193125-07-068126.txt : 20070329 0001193125-07-068126.hdr.sgml : 20070329 20070329091305 ACCESSION NUMBER: 0001193125-07-068126 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20070329 DATE AS OF CHANGE: 20070329 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 000-10824 FILM NUMBER: 07725826 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 425 1 d425.htm FORM 425 Form 425

Filed by Oscient Pharmaceuticals Corporation
Pursuant to Rule 425 under the Securities Act of 1933, as amended
and deemed filed pursuant to Rule 13e-4 under the Securities Exchange Act of 1934, as amended
Subject Company: Oscient Pharmaceuticals Corporation
Commission File No.: 333-141308


Oscient Pharmaceuticals Corporation has filed a registration statement (including a preliminary prospectus) with the SEC for the exchange offers to which this communication relates. Before you decide whether to participate in the exchange offers, you should read the preliminary prospectus in that registration statement and other documents Oscient has filed with the SEC for more complete information about Oscient and the exchange offers. You may get these documents for free by visiting EDGAR on the SEC Website at “www.sec.gov”. Alternatively, Oscient or the information agent will arrange to send you the preliminary prospectus if you request it by calling toll-free 1-888-549-6633.

The following is a script to answer questions from holders of Oscient’s 5% Convertible Promissory Notes due 2009, the existing 2009 notes, in connection with the pending exchange offer pursuant to which holders can exchange their existing 2009 notes for Oscient’s 3.50% Convertible Senior Notes due 2001, the new notes.

 

Question: In considering whether or not to exchange my existing 2009 notes for the new notes, how do I value my existing 2009 notes?

 

Answer: There are number of ways to value any bond, including our existing 2009 notes, and we cannot value the notes for you. There is no existing liquid market for the existing 2009 notes and therefore no market price for the 2009 notes. You will need to consider many different factors in determining the value of the existing 2009 notes and you should carefully consider the information contained in the preliminary prospectus relating to the exchange offer. In particular you should consider the differences between the existing 2009 notes and the new notes which are summarized in the preliminary prospectus under the heading “Comparison of New Notes and Existing Notes” and the risk factors included in the preliminary prospectus. Various theoretical methodologies may also be employed by holders of the existing 2009 notes to calculate the net present value of the existing 2009 notes. The outputs of the various theoretical methodologies will vary widely based on the assumptions that a 2009 bondholder may make. Two examples of publicly-available financial models that illustrate these valuation methodologies may be found at the following websites: “http://www.thi.com/cgi-bin/bond.pl” and http://www.calculator.com/calcs/bondcalc.html.” Neither the Company nor the Dealer-Manager make any representation as to the accuracy or usefulness of these financial models and are not providing any guidance as to the assumptions that may be used in these models. These website addresses are provided solely for informational purposes and the websites are not intended in any manner to be a part of the prospectus or any other materials that may be used in connection with the exchange offer for our existing 2009 notes.

* * * * *

A tender offer statement, registration statement (and the prospectus included therein), related letters of transmittal and other offering documents relating to the new notes and the exchange offers have been filed with the SEC but the registration statement has not yet become effective. The exchange offers may not be completed and the new notes may not be issued prior to the time the registration statement becomes effective.

-----END PRIVACY-ENHANCED MESSAGE-----